Date published: 2025-11-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

Vmn1r30 Inhibitors

Vmn1r30 inhibitors are a class of chemical compounds that specifically target the Vmn1r30 receptor, a member of the vomeronasal 1 receptor family, which is part of the broader group of G-protein-coupled receptors (GPCRs). The Vmn1r receptors are primarily involved in chemosensory detection, playing a role in the processing of chemical signals such as pheromones in certain species. The Vmn1r30 receptor is located in the vomeronasal organ (VNO), a specialized structure in some vertebrates responsible for detecting chemical cues. Inhibitors of Vmn1r30 function by binding to the receptor or altering its interaction with natural ligands, thereby preventing the receptor from transmitting its normal signaling cascades in response to chemical stimuli.

The development and study of Vmn1r30 inhibitors involve exploring the receptor's molecular structure and its binding interactions with various ligands. Structural biology techniques such as molecular modeling, ligand docking studies, and biochemical assays are used to characterize how these inhibitors block receptor function. These inhibitors can be valuable for probing the specific roles of Vmn1r30 in the broader context of chemosensory pathways, helping to clarify how the receptor contributes to cellular signaling and behavioral responses to chemical stimuli. By inhibiting this receptor, researchers can gain a deeper understanding of the molecular mechanisms governing chemosensory detection, receptor activation, and the subsequent biological processes without referencing any external applications. This precise targeting of Vmn1r30 provides essential insights into the role of individual receptors within the complex network of GPCR-mediated signaling systems.

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Propranolol

525-66-6sc-507425
100 mg
$180.00
(0)

Beta-adrenergic receptor antagonist, can modulate GPCR signaling, potentially affecting Vmn1r30 indirectly.

Cimetidine

51481-61-9sc-202996
sc-202996A
5 g
10 g
$62.00
$86.00
1
(1)

Histamine H2 receptor antagonist, may alter GPCR-mediated processes, potentially impacting Vmn1r30.

Ondansetron

99614-02-5sc-201127
sc-201127A
10 mg
50 mg
$80.00
$326.00
1
(0)

Serotonin receptor antagonist, might affect GPCR signaling pathways, influencing Vmn1r30 indirectly.

Yohimbine hydrochloride

65-19-0sc-204412
sc-204412A
sc-204412B
1 g
5 g
25 g
$50.00
$168.00
$520.00
2
(1)

Alpha-2 adrenergic receptor antagonist, could affect noradrenergic signaling, possibly related to Vmn1r30.

Forskolin

66575-29-9sc-3562
sc-3562A
sc-3562B
sc-3562C
sc-3562D
5 mg
50 mg
1 g
2 g
5 g
$76.00
$150.00
$725.00
$1385.00
$2050.00
73
(3)

Activates adenylate cyclase, increasing cAMP levels, which could modulate GPCR signaling affecting Vmn1r30.

Losartan

114798-26-4sc-353662
100 mg
$127.00
18
(1)

Angiotensin II receptor antagonist, might modulate GPCR pathways, potentially influencing Vmn1r30 activity.

Verapamil

52-53-9sc-507373
1 g
$367.00
(0)

Calcium channel blocker, could affect calcium signaling pathways, potentially related to Vmn1r30.

Pertussis Toxin (islet-activating protein)

70323-44-3sc-200837
50 µg
$442.00
3
(1)

Inhibits Gi/o proteins, could affect GPCR-mediated signaling pathways involved with Vmn1r30.

Amiloride

2609-46-3sc-337527
1 g
$290.00
7
(1)

Sodium channel blocker, might indirectly influence signaling mechanisms relevant to Vmn1r30.

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$66.00
$219.00
$417.00
97
(3)

PI3K inhibitor, could affect downstream signaling pathways that might impact Vmn1r30 function.